

Fasenra[®] (Benralizumab) Prior Authorization Form

Member Name: _____ **Date of Birth:** _____ **Member ID#:** _____

Drug Information

Physician billing (HCPCS code: _____) Pharmacy billing (NDC: _____)

Dose: _____ **Regimen:** _____ **Start Date:** _____

Billing Provider Information

Provider NPI: _____ **Provider Name:** _____

Provider Phone: _____ **Provider Fax:** _____

Prescriber Information

Prescriber NPI: _____ **Prescriber Name:** _____

Prescriber Phone: _____ **Prescriber Fax:** _____ **Specialty:** _____

Criteria

Compliance with all of the prior authorization criteria is a condition for payment for this drug by SoonerCare. All information must be provided and SoonerCare may verify through further requested documentation. The member's drug history will be reviewed prior to approval. **Initial approvals will be for the duration of six months.**

1. What is the diagnosis for which the medication is being prescribed?
 - Severe eosinophilic phenotype asthma**
 - Other, please list:** _____
2. Will benralizumab be used as add-on maintenance treatment for severe eosinophilic phenotype asthma?
Yes ___ No ___
3. If yes, please indicate member's daily medications and dose prescribed for the treatment of this diagnosis:
Drug/Dose: _____ Drug/Dose: _____
4. Baseline blood eosinophil count: _____ Date Determined: _____
5. Has the member been evaluated by an allergist, pulmonologist, or pulmonary specialist within the last 12 months (or an advanced care practitioner with a supervising physician who is an allergist, pulmonologist, or pulmonary specialist)? Yes ___ No ___
6. If yes, please include name of specialist: _____
7. Is member compliant with a medium-to-high-dose inhaled corticosteroid (ICS) plus at least 1 additional controller medication? Yes ___ No ___
8. Does member require daily systemic corticosteroids despite compliant use of a medium-to-high-dose ICS plus at least 1 additional controller medication? Yes ___ No ___
9. If answer is 'no' to previous question, please list number and dates of exacerbations requiring systemic corticosteroids within last 12 months: Number: _____ Dates of exacerbations: _____
10. Please check all that apply:
 - Member has failed a medium-to-high-dose ICS used compliantly for at least the past 12 months
- Drug/Dose: _____
 - Member has failed at least 1 other asthma controller medication used in addition to the medium-to-high-dose ICS compliantly for at least the past 3 months
- Drug/Dose: _____
11. For **Fasenra[®] prefilled syringe**, will it be administered in a health care setting by a health care professional prepared to manage anaphylaxis? Yes ___ No ___
12. For **Fasenra[®] prefilled autoinjector pen**, has member or caregiver been trained by a health care professional on subcutaneous administration, monitoring for any allergic reactions, and storage of Fasenra[®] prefilled autoinjector pen? Yes ___ No ___

Members must be adherent for continued approval. Compliance will be evaluated for continued approval.

Prescriber Signature: _____ **Date:** _____
(By signature, the physician confirms the criteria information above is accurate and verifiable in patient records.)
Please do not send in chart notes. Specific information/documentation will be requested if necessary. Failure to complete this form in full will result in processing delays.

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy
Pharmacy Management Consultants
Product Based Prior Authorization Unit

Fax: 1-800-224-4014
Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.